MDMA godfather Alexander Shulgin's legacy

June 6, 2014 by Simon Cotton
Credit: Paul Faith/PA

The first time ecstasy impinged on the public consciousness in Britain was in November 1995, when an 18-year old Essex schoolgirl named Leah Betts died a few days after taking a tablet at a birthday party. The cause of her death was drinking seven litres of water in 90 minutes, resulting in brain damage – drinking plenty of water was recommended to combat dehydration at rave parties – but ecstasy was widely blamed.

On June 2, the godfather of ecstasy, Alexander Shulgin died. Often called "Sasha", his name is inextricably linked to the drug. The chemical technically abbreviated as MDMA (3,4-methylenedioxy-N-methylamphetamine) exploded onto the popular musical scene during the 1980s, first in the US, then moving to Europe, originally associated with dance clubs in Ibiza.

But Shulgin deserves to be remembered for more than this one chemical. He trained as a chemist and obtained a PhD in biochemistry at the University of California, Berkeley. He had a successful research career, working for Dow Chemicals as a synthetic chemist, when he created Zectran, the first biodegradeable pesticide, and a very profitable one. In his spare time, Shulgin began to investigate psychoactive , a pursuit influenced by his sampling mescaline.

Maker of highs

What mescaline and ecstasy have in common is what chemists would recognise as a phenylethylamine backbone, a feature shared with Zectran. Phenylethylamine is a molecule containing a hexagonal ring of carbons – a "benzene ring" – to which is attached a side chain containing two more carbon atoms and also bearing an amine group (a nitrogen attached to two hydrogen atoms). It occurs in nature – including the human body – in small amounts. It is a stimulant within the body, though it is rapidly broken down by the liver, so it doesn't hang around for long.

Once synthetic chemistry started to develop from the late 19th century, chemists started to make molecules with the same core as phenylethylamine but with additional groups – a carbon added here, or a chain of a couple of carbons there. Amphetamine was first made in 1887, and methamphetamine, ecstasy and many more followed close at its heels. These molecules do not occur in nature, so our body doesn't know how to break them down, so they have more pronounced stimulant effects. Amphetamine started to be used as a decongestant and anti-asthmatic medicine in the late 1920s and people soon discovered its potential for abuse.

While he was still working for Dow – they parted company in 1966 – Shulgin was already testing different molecules for their psychoactive properties. He obtained a licence from the US Drug Enforcement Agency for a laboratory at home and went on to prepare hundreds of variants on the amphetamine unit. He tested them on himself and a few willing friends, noting down the effect of each dose, whether pleasant or not. Very small changes in the molecular structure can produce dramatic changes in the effect of the molecule within the human body. Although Shulgin did not discover ecstasy – that was done by the pharmaceutical giant Merck in 1912 – he pioneered the exploration of its mind-altering properties.

Bad medicine?

In 1991 Shulgin, along with his wife Ann, published a remarkable book, with an equally remarkable title, PIHKAL, short for Phenylethylamines I Have Known And Loved. The first part of it is semi-autobiographical, describing two characters – Dr Alexander Borodin, known as "Shura", and his wife Alice. It is for the reader to surmise how closely these two characters correspond to Sasha and Ann.

In total contrast, the second part of the book consists of the complete synthetic details needed to make MDMA and 178 other substituted phenylethylamines, together with accounts of the effect of varying doses of these substances upon the tester. In his foreword to the book, David Nichols of Purdue University, himself an internationally regarded expert on psychoactive molecules, comments, "there has never been a work like it", going on to add that following recent legislation, it was possible we might never see another.

The DEA evidently had a love-hate relationship with Shulgin, who had actually synthesised molecules for them and acted as an adviser. This synergistic relationship broke down following the publication of PIHKAL, which the DEA regarded as a cookbook for illicit laboratories, and they busted his lab in 1994.

We need to remember that molecules are morally neutral, it is the use to which they are put that matters. Chemistry is the ultimate creative science, making materials that have never existed before. Chemists like Shulgin and Nichols have constructed new molecules with the aim of creating useful medicinal substances, but those same molecules have been abused by illicit drug manufacturers, whose sole motive has been financial gain and without regard to the lives of those people consuming them.

Shulgin maintained that his work was motivated by a belief that MDMA and other molecules could be useful aids to psychotherapists and in recent years evidence has emerged that MDMA may be useful in the treatment of post-traumatic stress disorder, whether victims of war or sexual assault. MDMA may yet prove to be Alexander Shulgin's most valuable legacy.

Explore further: Ecstasy chemist Shulgin, 88, dies in California (Update)

Related Stories

Ecstasy derivative targets blood cancers

October 6, 2011

(Medical Xpress) -- A team of UWA researchers have found they may be able to alter the club drug ‘ecstasy’ to kill certain types of blood cancers at the same time boosting the potency and reducing the psychoactivity.

MDMA can be fatal in warm environments

June 4, 2014

A moderate dose of MDMA, commonly known as Ecstasy or Molly, that is typically nonfatal in cool, quiet environments can be lethal in rats exposed to conditions that mimic the hot, crowded, social settings where the drug is ...

Researchers tackle designer drug craze

July 16, 2012

(Medical Xpress) -- President Obama signed a bill into law this week designating certain chemicals found in designer drugs as FDA-controlled substances.

Recommended for you

Artificial photosynthesis gets big boost from new catalyst

November 20, 2017

A new catalyst created by U of T Engineering researchers brings them one step closer to artificial photosynthesis—a system that, just like plants, would use renewable energy to convert carbon dioxide (CO2) into stored chemical ...

Scientific advances can make it easier to recycle plastics

November 17, 2017

Most of the 150 million tons of plastics produced around the world every year end up in landfills, the oceans and elsewhere. Less than 9 percent of plastics are recycled in the United States, rising to about 30 percent in ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jun 07, 2014
in recent years evidence has emerged that MDMA may be useful in the treatment of post-traumatic stress disorder

i loled at that - the drug has been used in therapies for decades with huge amount of documented results, primarily hailed as miracle substance and stubornly ignored by goverments, so hardly recent years and ofc it entered public domain in a similar fashion - through theraphies and word of mouth.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.